Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.36 |
| ▸ | WNT1 | P04628 | 13/20 | 0.36 |
| ▸ | GSK3B | P49841 | 12/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618869 | 0.93 | DYRK1A (0.42) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL17767959 | 0.93 | DYRK1A (0.42) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL19689662 | 0.89 | GSK3B (0.39) | DYRK1AWNT1GSK3BWNT3AABL1 | |
| SCHEMBL17618870 | 0.89 | DYRK1A (0.35) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL17618694 | 0.87 | BRAF (0.41) | DYRK1AWNT1GSK3BWNT3A | |
| SCHEMBL19689693 | 0.87 | DYRK1A (0.34) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL17768118 | 0.86 | WNT3A (0.36) | WNT3AABL1MAPK1 | |
| SCHEMBL16754414 | 0.84 | FAAH (0.43) | WNT3AABL1 | |
| SCHEMBL17778385 | 0.83 | WNT3A (0.40) | WNT3AABL1 | |
| SCHEMBL16238798 | 0.83 | WNT3A (0.40) | WNT3AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 3048/4885WNT1 3338/4885GSK3B 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.